Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Prucalopride - MOTEGRITY official label
Product / population
Prucalopride - MOTEGRITY official label; selected renal source sections only, not a complete prescribing monograph.
Renal method
Measured CrCl, mL/min, from 24-hour urine collection in the renal trial. Not automatically Cockcroft-Gault or indexed eGFR.
Source revision
Prescribing information revised 7/2025.
Retrieved
2026-09-08
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
MOTEGRITY: measured clearance and a separate official-source recovery
The official renal study used 24-hour urinary measured creatinine clearance. The short RX rendering did not supply its renal instructions and remains held.
What to reconcile: Keep the official supplement and dialysis avoidance separate from the incomplete RX page. Do not silently relabel measured clearance as Cockcroft-Gault or indexed eGFR.
DailyMed / Takeda Pharmaceuticals America, Inc. · Prucalopride - MOTEGRITY official label; selected renal source sections only, not a complete prescribing monograph.
Renal method: Measured CrCl, mL/min, from 24-hour urine collection in the renal trial. Not automatically Cockcroft-Gault or indexed eGFR. Source date: Prescribing information revised 7/2025. Retrieved: 2026-09-08
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
For adults with chronic idiopathic constipation, the dose is 2 mg once daily; at CrCl <30 mL/min, reduce to 1 mg once daily. No adjustment is required at CrCl >=30. Avoid use in ESRD requiring dialysis. The renal trial used CrCl determined by 24-hour urine collection, not an automatically assumed Cockcroft-Gault estimate. Assess intestinal contraindications and monitor new or worsening depression or suicidal symptoms; renal reduction does not remove these precautions.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.